T he optimal degree of revascularization for patients with multivessel coronary artery disease is not well established. Although there is growing evidence to support early and more complete revascularization of significant noninfarct artery stenoses among selected patients with STsegment elevation myocardial infarction (STEMI) (1, 2) , there are few prospective studies evaluating patients with acute coronary syndromes or stable coronary disease to support a similar approach (3, 4) . Vascular and AstraZeneca. Dr. Ayalon has reported that he has no relationships relevant to the contents of this paper to disclose. When advances in technology essentially eliminate stent thrombosis and decrease in-stent restenosis to a few percent, or allow us to identify and
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